Xeris Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Xeris Pharmaceuticals Inc cash flow-to-debt ratio. Xeris Pharmaceuticals Inc (XERS) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2026, meaning its operating cash flow of $8.26 Million could theoretically repay 0% of its total liabilities ($421.64 Million) in one year. Check cash flow quality index of Xeris Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Xeris Pharmaceuticals Inc (2016–2025)
Cash flow-to-debt ratio of Xeris Pharmaceuticals Inc from 2016 to 2025. Historical debt coverage capacity for Xeris Pharmaceuticals Inc across 10 annual periods. Check how aggressively does Xeris Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Xeris Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Xeris Pharmaceuticals Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Xeris Pharmaceuticals Inc. For the full cash flow conversion analysis, see XERS cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | $28.63 Million | $369.84 Million | ▲ +173.8% |
| 2024 | -0.10x | $-36.98 Million | $352.68 Million | ▲ +26.5% |
| 2023 | -0.14x | $-47.02 Million | $329.38 Million | ▲ +58.5% |
| 2022 | -0.34x | $-102.89 Million | $299.33 Million | ▲ +24.8% |
| 2021 | -0.46x | $-95.53 Million | $209.13 Million | ▲ +46.4% |
| 2020 | -0.85x | $-80.56 Million | $94.55 Million | ▲ +22.8% |
| 2019 | -1.10x | $-104.35 Million | $94.55 Million | ▲ +12.5% |
| 2018 | -1.26x | $-56.28 Million | $44.62 Million | ▼ -425.9% |
| 2017 | -0.24x | $-24.66 Million | $102.83 Million | ▲ +2.4% |
| 2016 | -0.25x | $-16.09 Million | $65.47 Million | — |